Johnson & Johnson To Pay $2.2 Billion Fine To Resolve Drug Marketing Case

The government alleged that the drug company and its subsidiaries promoted psychiatric medications for uses that had not been approved by the Food and Drug Administration.

Los Angeles Times: Johnson & Johnson To Pay $2.2 Billion To Settle Federal Cases
The world's eighth-largest drug maker, Johnson & Johnson, has agreed to pay the U.S. government $2.2 billion to settle cases in which the government has alleged that the company and its subsidiaries promoted powerful psychiatric medications for uses not approved by the Food and Drug Administration and offered financial kickbacks for physicians who prescribed those medications frequently (Healy, 11/4).

CQ HealthBeat: Johnson & Johnson Faces Fines For Illegally Marketing Drugs And Playing Kickbacks
Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil claims that they marketed three drugs for uses that the Food and Drug Administration did not approve, federal officials said Monday (Adams, 11/4).

And in other legal action, another company is seeking to end a lawsuit.

The Wall Street Journal: Rural/Metro Strikes Deal To Settle Whistleblower Suit
Rural/MetroCorp. is seeking bankruptcy-court approval to settle a whistleblower lawsuit over the alleged submission of false Medicare claims. The ambulance company would pay $8 million to the U.S. Department of Justice under the settlement, which would resolve a whistleblower lawsuit against two Rural/Metro subsidiaries, according to court papers filed Fri (Palank, 11/4).

This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.